Amgen Inc. (AMGN): Earnings Whisper

Biotechnology giant Amgen Inc. (AMGN) is scheduled to release its second quarter 2015 results after the close on Thursday, July 30th. The company is expected to report revenue of $5.31 billion. Similarly, the EPS is projected at $2.42. A year ago, Amgen earned $2.37 a share. The Street’s estimates for the quarter reflect a year-over-year EPS and revenue increase of 2.10% and 2.50%, respectively. Meanwhile, reports a whisper number of $2.48 per share.

As a quick reminder, Amgen reported 1Q/15 EPS of $2.48, $0.38 better than the Street’s consensus estimate of $2.10. Revs rose 11.28% year-over-year to $5.03 billion from $4.52 billion vs. the $4.91 billion consensus.

On valuation measures, Amgen Inc. shares are currently priced at 22.92x this year’s forecasted earnings. Ticker has a PEG and forward P/E ratio of 1.59 and 16.04, respectively. Price/Sales for the same period is 6.34 while EPS is $7.41. Currently there are 10 analysts that rate AMGN a ‘Buy’, 11 rate it a ‘Hold’. No analyst rates it a ‘Sell’. AMGN has a median Wall Street price target of $183.00 with a high target of $210.00.

Over the past year, shares of Thousand Oaks, California-based firm have traded between a low of $124.76 and a high of $174.80 and are now at $169.85.

Shares are up 41.70% year-over-year and 8.75% year-to-date.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.